CML66 Activators
CML66 activators comprise a diverse array of chemical compounds that indirectly enhance the functional activity of CML66 through their influence on various signaling pathways. Forskolin and IBMX, by increasing intracellular cAMP levels, facilitate PKA activation, which can phosphorylate substrates within signaling cascades that CML66 may be involved in, thereby enhancing its activity. Similarly, PMA, by activating PKC, modifies the phosphorylation states of numerous proteins that may interact with or regulate CML66, leading to its functional enhancement. S1P, by acting on G-protein coupled receptors, initiates signaling that can activate MAPK and PI3K/Akt pathways, which might intersect with CML66's regulatory functions. EGCG and tyrosine kinase inhibitors like Genistein can shift signaling equilibrium by inhibiting competitive pathways or kinases, freeing CML66 to have increased activity.
In addition, the PI3K inhibitors LY294002 and Wortmannin may enhance CML66's functions by reducing negative feedback within signaling pathways, while U0126 could promote CML66 activation by shifting the focus of MAPK signaling. The modulation of intracellular calcium levels by A23187 andThapsigargin can also contribute to the enhancement of CML66 activity. Higher calcium levels activate calcium-dependent signaling pathways, which could intersect with CML66's role, leading to its activation. Staurosporine, although a broad-spectrum inhibitor, might selectively enhance CML66 pathways by inhibiting specific kinases that suppress pathways where CML66 is operative. Collectively, these activators work through their targeted effects on signaling molecules and pathways, leading to the indirect yet potent enhancement of CML66's functional activities in cellular processes.
SEE ALSO...
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Forskolin | 66575-29-9 | sc-3562 sc-3562A sc-3562B sc-3562C sc-3562D | 5 mg 50 mg 1 g 2 g 5 g | $78.00 $153.00 $740.00 $1413.00 $2091.00 | 73 | |
Forskolin directly elevates intracellular cAMP levels, which can enhance the protein CML66 by activating PKA that may phosphorylate proteins involved in signaling pathways regulated by CML66. | ||||||
IBMX | 28822-58-4 | sc-201188 sc-201188B sc-201188A | 200 mg 500 mg 1 g | $260.00 $350.00 $500.00 | 34 | |
IBMX functions as a non-selective inhibitor of phosphodiesterases, leading to increased cAMP levels which can enhance PKA activity. PKA then can activate pathways where CML66 is a participant, leading to its functional enhancement. | ||||||
PMA | 16561-29-8 | sc-3576 sc-3576A sc-3576B sc-3576C sc-3576D | 1 mg 5 mg 10 mg 25 mg 100 mg | $41.00 $132.00 $214.00 $500.00 $948.00 | 119 | |
PMA activates protein kinase C (PKC), which is involved in numerous signaling pathways. PKC activation can lead to the altered phosphorylation state of various substrates that may interact with or regulate CML66, thereby indirectly enhancing its activity. | ||||||
D-erythro-Sphingosine-1-phosphate | 26993-30-6 | sc-201383 sc-201383D sc-201383A sc-201383B sc-201383C | 1 mg 2 mg 5 mg 10 mg 25 mg | $165.00 $322.00 $570.00 $907.00 $1727.00 | 7 | |
S1P engages with G-protein coupled receptors and can initiate signaling cascades that result in the activation of MAPK and PI3K/Akt pathways. These pathways could intersect with processes regulated by CML66, enhancing its activity. | ||||||
(−)-Epigallocatechin Gallate | 989-51-5 | sc-200802 sc-200802A sc-200802B sc-200802C sc-200802D sc-200802E | 10 mg 50 mg 100 mg 500 mg 1 g 10 g | $43.00 $73.00 $126.00 $243.00 $530.00 $1259.00 | 11 | |
EGCG is a kinase inhibitor that can modulate the activity of various kinases within signaling pathways. Inhibition of competitive pathways could shift the equilibrium towards the activation of pathways in which CML66 is involved. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
LY294002 is a PI3K inhibitor that can increase the activity of downstream targets by reducing negative feedback. This could lead to an enhanced functional state of CML66 through indirect effects on signaling pathways. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $67.00 $223.00 $425.00 | 97 | |
Wortmannin is another PI3K inhibitor that operates similarly to LY294002, potentially leading to the indirect activation of signaling pathways involving CML66. | ||||||
A23187 | 52665-69-7 | sc-3591 sc-3591B sc-3591A sc-3591C | 1 mg 5 mg 10 mg 25 mg | $55.00 $131.00 $203.00 $317.00 | 23 | |
A23187 is a calcium ionophore that increases intracellular calcium levels, potentially activating calcium-dependent proteins and signaling pathways that could intersect with and enhance the activity of CML66. | ||||||
Staurosporine | 62996-74-1 | sc-3510 sc-3510A sc-3510B | 100 µg 1 mg 5 mg | $82.00 $153.00 $396.00 | 113 | |
Staurosporine is a broad-spectrum protein kinase inhibitor. By inhibiting certain kinases, it could lead to the selective enhancement of pathways in which CML66 is involved by lifting the inhibition on them. | ||||||
Genistein | 446-72-0 | sc-3515 sc-3515A sc-3515B sc-3515C sc-3515D sc-3515E sc-3515F | 100 mg 500 mg 1 g 5 g 10 g 25 g 100 g | $45.00 $164.00 $200.00 $402.00 $575.00 $981.00 $2031.00 | 46 | |
Genistein acts as a tyrosine kinase inhibitor, potentially enhancing the activity of CML66 by alleviating competitive tyrosine kinase signaling that might otherwise suppress pathways in which CML66 is involved. | ||||||